[an error occurred while processing this directive] | [an error occurred while processing this directive]
Discussion on current problems of neoadjuvant chemoradiotherapy for esophageal carcinoma
Gong Heyi, Li Baosheng
Department of Radiation Oncology, Cancer Hospital Affiliated to Shandong First Medical University, Shandong Provincial Key Laboratory of Radiation Oncology, Shandong Cancer Institute, Ji′nan 250117, China
Abstract Neoadjuvant chemoradiotherapy is the preferred treatment mode for the diagnosis and treatment of locally advanced operable esophageal carcinoma recommended by many guidelines. However, some problems remain to be further explored. In this article, current problems perplexing clinical practice were sorted out, aiming to provide constructive suggestions for the smooth development of neoadjuvant chemoradiotherapy for esophageal carcinoma in the future.
Corresponding Authors:
Li Baosheng, Email:baoshli1963@163.com
Cite this article:
Gong Heyi,Li Baosheng. Discussion on current problems of neoadjuvant chemoradiotherapy for esophageal carcinoma[J]. Chinese Journal of Radiation Oncology, 2021, 30(8): 759-763.
Gong Heyi,Li Baosheng. Discussion on current problems of neoadjuvant chemoradiotherapy for esophageal carcinoma[J]. Chinese Journal of Radiation Oncology, 2021, 30(8): 759-763.
[1] Shapiro J, van Lanschot JJB, Hulshof MC, et al. Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS):long-term results of a randomised controlled trial[J]. Lancet Oncol, 2015, 16(9):1090-1098. DOI:10.1016/S1470-2045(15)00040-6. [2] Yang H, Liu H, Chen Y, et al. Neoadjuvant chemoradiotherapy followed by surgery versus surgery alone for Locally advanced squamous cell carcinoma of the esophagus (NEOCRTEC5010):a phase Ⅲ multicenter, randomized, open-Label clinicalTrial[J]. J Clin Oncol, 2018, 36(27):2796-2803. DOI:10.1200/JCO.2018.79.1483. [3] Li Q, Zhu S, Li S, et al. Elective nodal irradiation provides a superior therapeutic modality for lymph node positivity esophageal squamous cell carcinoma patients receiving definitive radiotherapy versus involved-field irradiation[J]. Medicine (Baltimore), 2019, 98(3):e14080. DOI:10.1097/MD.0000000000014080. [4] 中国医师协会放射肿瘤治疗医师分会,中华医学会放射肿瘤治疗学分会,中国抗癌协会肿瘤放射治疗专业委员会. 中国食管癌放射治疗指南(2019年版)[J]. 国际肿瘤学杂志,2019, 46(7):385-398. DOI:10.3760/cma.j.issn.1673-422X.2019.07.001. Radiation Oncologists Branch of Chinese Physician Association. Radiation Oncology Branch of Chinese Medical Association. Cancer Radiotherapy Committee of China Anticancer Association. China esophageal cancer radiology guidelines (2019 ed)[J]. Int J Oncology, 2019, 46(7):385-398. DOI:10.3760/cma.j.issn.1673-422X.2019.07.001. [5] Yanagi M, Sasaki K, Uchikado Y, et al. Effect of neoadjuvant chemoradiotherapy on lymph node micrometastases in thoracic esophageal cancer[J]. Anticancer Res, 2018, 38(2):893-900. DOI:10.21873/anticanres.12299. [6] Liu T, Ding S, Dang J, et al. Elective nodal irradiation versus involved-field irradiation in patients with esophageal cancer receiving neoadjuvant chemoradiotherapy:a network meta-analysis[J]. Radiat Oncol, 2019, 14(1):176. DOI:10.1186/s13014-019-1388-8. [7] Buckstein M, Rhome R, Ru M, et al. Neoadjuvant chemoradiation radiation dose levels for surgically resectable esophageal cancer:predictors of use and outcomes[J]. Dis Esophagus, 2018, 31(5):dox148. DOI:10.1093/dote/dox148. [8] Paireder M, Jomrich G, Kristo I, et al. Modification of preoperative radiochemotherapy for esophageal cancer (CROSS protocol) is safe and efficient with no impact on surgical morbidity[J]. Strahlenther Onkol, 2020, 196(9):779-786. DOI:10.1007/s00066-020-01594-z. [9] Haisley KR, Hart KD, Nabavizadeh N, et al. Neoadjuvant chemoradiotherapy with concurrent cisplatin/5-fluorouracil is associated with increased pathologic complete response and improved survival compared to carboplatin/paclitaxel in patients with locally advanced esophageal cancer[J]. Dis Esophagus, 2017, 30(7):1-7. DOI:10.1093/dote/dox015. [10] Ranney DN, Mulvihill MS, Yerokun BA, et al. Surgical resection after neoadjuvant chemoradiation for oesophageal adenocarcinoma:what is the optimal timing?[J]. Eur J Cardiothorac Surg, 2017, 52(3):543-551. DOI:10.1093/ejcts/ezx132. [11] Haisley KR, Laird AE, Nabavizadeh N, et al. Association of intervals between neoadjuvant chemoradiation and surgical resection with pathologic complete response and survival in patients with esophageal cancer[J]. JAMA Surg, 2016, 151(11):e162743. DOI:10.1001/jamasurg.2016.2743. [12] Franko J, McAvoy S. Timing of esophagectomy after neoadjuvant chemoradiation treatment in squamous cell carcinoma[J]. Surgery, 2018, 164(3):455-459. DOI:10.1016/j.surg.2018.04.026. [13] Vellayappan BA, Soon YY, Ku GY, et al. Chemoradiotherapy versus chemoradiotherapy plus surgery for esophageal cancer[CD]. Cochrane Database Syst Rev, 2017, 8(8):CD010511. DOI:10.1002/14651858. [14] Wang J, Qin J, Jing S, et al. Clinical complete response after chemoradiotherapy for carcinoma of thoracic esophagus:is esophagectomy always necessary? A systematic review and meta-analysis[J]. Thorac Cancer, 2018, 9(12):1638-1647. DOI:10.1111/1759-7714.12874. [15] Levinsky NC, Wima K, Morris MC, et al. Outcome of delayed versus timely esophagectomy after chemoradiation for esophageal adenocarcinoma[J]. J Thorac Cardiovasc Surg, 2020, 159(6):2555-2566. DOI:10.1016/j.jtcvs.2019.09.169. [16] Heethuis SE, Goense L, van Rossum PSN, et al. DW-MRI and DCEMRI are of complementary value in predicting pathologic response to neoadjuvant chemoradiotherapy for esophageal cancer[J]. Acta Oncol, 2018, 57(9):1201-1208. DOI:10.1080/0284186X.2018.1473637. [17] Heneghan HM, Donohoe C, Elliot J, et al. Can CT-PET and endoscopic assessment post-neoadjuvant chemoradiotherapy predict residual disease in esophageal cancer?[J]. Ann Surg, 2016, 264(5):831-838. DOI:10.1097/SLA.000000000000 1902. [18] Qian D, Wang Y, Zhao G, et al. Tumor remission and tumor-infiltrating lymphocytes during chemoradiation therapy:predictive and prognostic markers in locally advanced esophageal squamous cell carcinoma[J]. Int J Radiat Oncol Biol Phys, 2019, 105(2):319-328. DOI:10.1016/j.ijrobp.2019.06.079. [19] Yu JP, Lu WB, Wang JL, et al. Pathologic response during chemoradiotherapy and variation of serum VEGF levels could predict effects of chemo-radiotherapy in patients with esophageal cancer[J]. Asian Pac J Cancer Prev, 2015, 16(3):1111-1116. DOI:10.7314/apjcp.2015.16.3.1111. [20] Noordman BJ, Spaander MCW, Valkema R, et al. Detection of residual disease after neoadjuvant chemoradiotherapy for oesophageal cancer (preSANO):a prospective multicentre, diagnostic cohort study[J]. Lancet Oncol, 2018, 19(7):965-974. DOI:10.1016/S1470-2045(18)30201-8. [21] 中华人民共和国2019年国民经济和社会发展统计公报[R].北京:中华人民共和国国家统计局,2020. Statistical Bulletin of the National Economic and Social Development in 2019[R]. Beijing:National Bureau of Statistics of the People′s Republic of China, 2020. [22] Miyata H, Yamasaki M, Makino T, et al. Clinical outcome of esophagectomy in elderly patients with and without neoadjuvant therapy for thoracic esophageal cancer[J]. Ann Surg Oncol, 2015, 22(Suppl 3):S794-801. DOI:10.1245/s10434-015-4769-8.
2021, Vol. 30 
